Clarivate
CLVT | NYSE
$1.93
+$0.04 (+2.12%)
At close: Sep 21, 2026, 4:00 PM ET
$1.92
-$0.01 (-0.52%)
Pre-market:
Sep 22, 2026, 4:44 AM ET
Company Profile
Clarivate Plc operates as a prominent information services and analytics firm, furnishing structured data and insights. Its core mission is to facilitate the discovery, safeguard the intellectual property, and enable the commercialization of scientific research, innovations, and established brands. The company's portfolio includes the extensive Web of Science suite, a collection of essential tools such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio. These are designed to support organizations throughout the entire research lifecycle, from initial planning and funding to execution and utilization. Within the Life Sciences domain, Clarivate provides specialized products like Cortellis and Newport Integrity. These platforms cater to pharmaceutical and biotechnology companies, empowering their research endeavors, supplying vital market intelligence, and facilitating competitive monitoring during the development and launch phases of novel drugs. Its Derwent product line, comprising Derwent Innovation, Techstreet, and IP Professional Services, is dedicated to intellectual property management. These tools enable customers to evaluate the originality of potential products, establish their freedom to operate within design parameters, secure patent protection, analyze the competitive technological landscape, and ensure adherence to essential industry standards. Complementing these, CompuMark delivers trademark screening, search, and monitoring solutions vital for businesses and legal firms. Meanwhile, MarkMonitor empowers enterprises to establish, manage, optimize, and fortify their digital presence. Clarivate's diverse clientele spans government agencies, academic institutions, life science enterprises, and research and development corporations worldwide, with operations across the Americas, Middle East, Africa, Europe, and Asia Pacific regions. The company, initially known as Clarivate Analytics Plc, rebranded to Clarivate Plc in May 2020. It maintains its headquarters in London, United Kingdom.
Key Executives
| Name | Position |
|---|---|
| Matitiahu Shem Tov | Chief Executive Officer & Director |
| Jonathan Collins | Executive Vice President & Chief Financial Officer |
| Michael Easton | Executive Vice President & Chief Financial Officer |
| William E. Graff | Executive Vice President & Chief Information Officer |
| Bar Veinstein | President of Academia & Government |
| Darien Krimmert | Senior Vice President & Head of People |
| Gwenan White | Senior Vice President of Communications & Brand |
| Henry Levy | President of Life Sciences & Healthcare |
| John Doulamis | Senior Vice President & General Counsel |
| Mark J. Donohue | Vice President of Investor Relations |
| Maroun S. Mourad | Advisor |
| Matthew Lisowski | Senior VP & Chief Accounting Officer |
| Tabita Andersson | Senior Vice President of Communications & Brand |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 17, 2026 | 4 | Filing |
| Aug 14, 2026 | 3 | Filing |
| Aug 10, 2026 | 4 | Filing |
| Aug 05, 2026 | 4 | Filing |
| Jul 29, 2026 | 8-K | Current Report |
| Jul 29, 2026 | 10-Q | Quarterly Report |
| Jul 29, 2026 | 8-K | Current Report |
| Jul 06, 2026 | 8-K | Current Report |
Clarivate
| Country | United Kingdom |
| IPO Date | Oct 28, 2018 |
| Industry | Information Technology Services |
| Sector | Technology |
| Employees | 12,000 |
| CEO | Matitiahu Shem Tov |
Contact Details
70 St. Mary Axe London,
GL EC3A 8BE United Kingdom
Stock Details
| Ticker Symbol | CLVT |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001764046 |
| CUSIP Number | G21810109 |
| ISIN Number | JE00BJJN4441 |
| SIC Code | 7374 |
Recent News
- 1 day ago / defenseworld.netClarivate PLC (NYSE:CLVT) Receives $3.02 Consensus Price Target from Brokerages
- 5 days ago / prnewswire.comClarivate Commences Offer to Purchase for Cash Certain of its Outstanding Debt Securities
- 5 days ago / gurufocus.comClarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific Breakthroughs
- 21 days ago / globenewswire.comAccuserve Solutions Appoints Maroun S. Mourad as an Independent Board Member
- 1 month ago / fool.comClarivate Director Cornick Buys 900,000 Shares for $1.7 Million. What Does This Tell Investors About the Outlook for 2026?
- 2 months ago / prnewswire.comClarivate Scales Agentic AI Across Cortellis to Advance Drug Development
- 2 months ago / marketbeat.comClarivate Q2 Earnings Call Highlights
- 2 months ago / seekingalpha.comClarivate Plc (CLVT) Q2 2026 Earnings Call Transcript
- 2 months ago / zacks.comClarivate (CLVT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
- 2 months ago / zacks.comClarivate PLC (CLVT) Q2 Earnings and Revenues Beat Estimates
Add to Watchlist
Select watchlists to add or remove CLVT